Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching

BACKGROUND: Traditional bortezomib, thalidomide, and dexamethasone (VTd) regimens for patients with newly diagnosed multiple myeloma (NDMM) include doses of thalidomide up to 200 mg/day (VTd‐label). Clinical practice has evolved to use a lower dose (100 mg/day) to reduce toxicity (VTd‐mod), which wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreau, Philippe, Hulin, Cyrille, Zweegman, Sonja, Hashim, Mahmoud, Hu, Yannan, Heeg, Bart, de Boer, Carla, Vanquickelberghe, Veronique, Kampfenkel, Tobias, He, Jianming, Lam, Annette, Cote, Sarah, Sonneveld, Pieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematologic Malignancy–Plasma Cell
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175692/
https://www.ncbi.nlm.nih.gov/pubmed/35846097
http://dx.doi.org/10.1002/jha2.129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175692/
https://www.ncbi.nlm.nih.gov/pubmed/35846097
http://dx.doi.org/10.1002/jha2.129

Ejemplares similares